Knockout and transgenic mice of Trp53: What have we learned about p53 in breast cancer?

Breast Cancer Research

Volumn 4, Issue 3, 2002, Pages 101-111

  Blackburn, Anneke C ^a   Jerry, D Joseph ^a  

^a UNIVERSITY OF MASSACHUSETTS   (United States)

Author keywords

Breast cancer; Knockout; p53; Transgenic

Indexed keywords

CARCINOGEN; HORMONE; PROTEIN P53;

ALLELE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; BREAST CANCER; BREAST CARCINOGENESIS; BREAST TUMOR; CANCER INCIDENCE; CANCER INHIBITION; CANCER THERAPY; CHEMICAL CARCINOGENESIS; CONTROLLED STUDY; FAMILIAL CANCER; GENE ACTIVITY; GENE MUTATION; GERM LINE; HORMONAL REGULATION; IN VIVO STUDY; INVOLUTION; KNOCKOUT MOUSE; MAMMARY GLAND; MOUSE; MOUSE STRAIN; MUTATION RATE; NONHUMAN; ONCOGENE; PHENOTYPE; PROTEIN DEFICIENCY; REVIEW; TRANSGENE; TRANSGENIC MOUSE; TUMOR SUPPRESSOR GENE;

ANIMALS; BREAST NEOPLASMS; DISEASE MODELS, ANIMAL; FEMALE; GENES, P53; MICE; MICE, KNOCKOUT; MICE, TRANSGENIC;

EID: 0036091565     PISSN: 14655411     EISSN: None     Source Type: Journal    
DOI: 10.1186/bcr427     Document Type: Review

References (64)

1. p53 mutations in breast cancer
2. Germ-line mutations of TP53 in Li-Fraumeni families: An extended study of 39 families
3. Li-Fraumeni syndrome and the role of the p53 tumor suppressor gene in cancer susceptibility
4. Li-Fraumeni syndrome - A molecular and clinical review
5. p53 mutation with frequent novel condons but not a mutator phenotype in BRCA1- and BRCA2-associated breast tumours
6. TP53 mutations in breast cancer associated with BRCA1 or BRCA2 germ-line mutations: Distinctive spectrum and structural distribution
7. Regulation of p53 downstream genes
8. The dual role model for p53 in maintaining genomic integrity
9. The cellular response to p53: The decision between life and death
10. Regulation of p53 in response to DNA damage
11. Retention of wild-type p53 in tumors from p53 heterozygous mice: Reduction of p53 dosage can promote cancer formation
12. Transgenic mouse model for studying the transcriptional activity of the p53 protein: Age- and tissue-dependent changes in radiation-induced activation during embryogenesis
13. Is p53 haploinsufficient for tumor suppression? Implications for the p53+/- mouse model in carcinogenicity testing
14. Androgen suppressed apoptosis is modified in p53 deficient mice
15. Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours
16. Tumor spectrum analysis in p53-mutant mice
17. Tumour incidence, spectrum and ploidy in mice with a large deletion in the p53 gene
18. Development of mammary tumors in BALB/c p53 heterozygous mice: A model for Li-Fraumeni Syndrome
19. Cre-mediated gene deletion in the mammary gland
20. Conditional control of gene expression in the mammary gland
21. Synergistic tumor suppressor activity of BRCA2 and p53 in a conditional mouse model for breast cancer
22. Studies of mouse mammary glands. II. Cytomorphology of mammary transplants in inguinal fat pads, nipple-excised host glands, and whole mammary-gland transplants
23. A mammary-specific model demonstrates the role of the p53 tumor suppressor gene in tumor development
24. Progesterone facilitates chromosome instability (aneuploidy) in p53 null normal mammary epithelial cells
25. A mutant p53 transgene accelerates tumour development in heterozygous but not nullizygous p53-deficient mice
26. Mutant p53 and genomic instability in a transgenic mouse model of breast cancer
27. null mice
28. Apoptosis and remodeling of mammary gland tissue during involution proceeds through p53-independent pathways
29. Cytoplasmic sequestration and functional repression of p53 in the mammary epithelium is reversed by hormonal treatment
30. Cell-cycling status of mammary epithelial cells predicts p53 responsiveness to gamma-radiation
31. Effects of genetic background on tumorigenesis in p53-deficient mice
32. A detailed study of loss of heterozygosity on chromosome 17 in tumours from Li-Fraumeni patients carrying a mutation to the TP53 gene
33. A transgenic mouse model for mammary carcinogenesis
34. Infrequent p53 mutations in 7,12-dimethylbenz[a]anthracene-induced mammary tumors in BALB/c and p53 hemizygous mice
35. Impact of ionizing radiation and genetic background on mammary tumorigenesis in p53-deficient mice
36. BRCA1-associated tumorigenesis: What have we learned from knockout mice?
37. Mammary tumor formation in p53- and BRCA1-deficient mice
38. Conditional mutation of Brca1 in mammary epithelial cells results in blunted ductal morphogenesis and tumour formation
39. P53, apoptosis, and breast cancer
40. neu/ERBB2 cooperates with p53-172H during mammary tumorigenesis in transgenic mice
41. Cooperative interaction between mutant p53 and des(1-3)IGF-I accelerates mammary tumorigenesis
42. Deficiency of p53 accelerates mammary tumorigenesis in Wnt-1 transgenic mice and promotes chromosomal instability
43. Increased tumor proliferation and genomic instability without decreased apoptosis in MMTV-ras mice deficient in p53
44. Absence of p53 in a mouse mammary tumor model promotes tumor cell proliferation without affecting apoptosis
45. p53-dependent apoptosis suppresses tumor growth and progression in vivo
46. Apoptosis or retinoblastoma: Alternative fates of photoreceptors expressing the HPV-16 E7 gene in the presence or absence of p53
47. Differential gene expression in mouse mammary adenocarcinomas in the presence and absence of wild type p53
48. WAF1/CIP1 enhances tumor cell proliferation and cyclin D1-associated kinase activity in a murine mammary cancer model
49. Preferential overexpression of a 172Arg → Leu mutant p53 in the mammary gland of transgenic mice results in altered lobuloalveolar development
50. Delay of dimethylbenz[a]anthracene-induced mammary tumorigenesis in transgenic mice by apoptosis induced by an unusual mutant p53 protein
51. The MMTV/c-myc transgene and p53 null alleles collaborate to induce T-cell lymphomas, but not mammary carcinomas in transgenic mice
52. Myc/p53 interactions in transgenic mouse mammary development, tumorigenesis and chromosomal instability
53. Breast cancer formation in transgenic animals induced by the whey acidic protein SV40 T antigen (WAP-SV-T) hybrid gene
54. WAP-TAg transgenic mice and the study of dysregulated cell survival, proliferation, and mutation during breast carcinogenesis
55. A transgenic mouse model for the ductal carcinoma in situ (DCIS) of the mammary gland
56. The C3(1)/SV40 T-antigen transgenic mouse model of mammary cancer: Ductal epithelial cell targeting with multistage progression to carcinoma
57. SV40 T-antigen induces breast cancer formation with a high efficiency in lactating and virgin WAP-SV-T transgenic animals but with a low efficiency in ovariectomized animals
58. The SV40 small t-antigen prevents mammary gland differentiation and induces breast cancer formation in transgenic mice; truncated large T-antigen molecules harboring the intact p53 and pRb binding region do not have this effect
59. Reduced p53 dosage associated with mammary tumor metastases in C3(1)/TAG transgenic mice
60. Apoptosis, p53, and tumor cell sensitivity to anticancer agents
61. p53 induction and apoptosis in response to radio- and chemotherapy in vivo is tumor-type-dependent
62. A farnesyltransferase inhibitor induces tumor regression in transgenic mice harboring multiple oncogenic mutations by mediating alterations in both cell cycle control and apoptosis
63. Genetic determinants of response to chemotherapy in transgenic mouse mammary and salivary tumors
64. Combination therapy with interleukin-2 and wild-type p53 expressed by adenoviral vectors potentiates tumor regression in a murine model of breast cancer